PATHOGENETIC MECHANISMS OF ACTION OF STRUCTURAL MODIFIED PROLONGED ACTION ANTI-INFLAMMATORY DRUGS (SYSADOA)

Abstract

The article is devoted to the combined indication of chondroitin drugs – Arthradol and glucosamine – ArthraCam in therapy of ostheoorthrosis. A symptom-modifying effect in monotherapy and in course therapy by Arthradol and ArthroCam on the background of non-steroid anti-inflammatory drugs.

Keywords

• ostheoarthrosis
• symptom-modifying prolonged action drugs
• arthradol
• arthracam